Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955780 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1TP53TDP1SMN1; SMN2 | |
| Acetone SCHEMBL28637824 | 0.92 | TP53 (0.58) | ALDH1A1MAPK1TP53TDP1SMN1; SMN2 | |
| SCHEMBL7137680 | 0.92 | ALDH1A1 (0.66) | ALDH1A1MAPK1TP53SMN1; SMN2CYP3A4 | |
| SCHEMBL8501497 | 0.90 | ALDH1A1 (0.63) | ALDH1A1MAPK1TP53SMN1; SMN2CYP3A4 | |
| SCHEMBL8501501 | 0.90 | ALDH1A1 (0.63) | ALDH1A1MAPK1TP53SMN1; SMN2CYP3A4 | |
| SCHEMBL232779 | 0.90 | TP53 (0.64) | ALDH1A1TP53TDP1SMN1; SMN2CYP3A4 | |
| SCHEMBL3291219 | 0.88 | ALDH1A1 (0.66) | ALDH1A1MAPK1TP53SMN1; SMN2CYP3A4 | |
| Hydrochloric Acid SCHEMBL3088495 | 0.88 | TP53 (0.62) | ALDH1A1TP53TDP1SMN1; SMN2CYP3A4 | |
| SCHEMBL9133420 | 0.88 | TP53 (0.62) | ALDH1A1TP53TDP1SMN1; SMN2CYP3A4 | |
| Hydrochloric Acid SCHEMBL2299193 | 0.88 | TP53 (0.62) | ALDH1A1TP53TDP1SMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120157484-A | Nickel-titanium alloy reinforced nano silicon carbide composite ceramic material and preparation process thereof | 苏州奥耐特碳化硅陶瓷科技有限公司 | 2025-06-17 | — | — | CN | claimed |
| CN-120157484-A | Nickel-titanium alloy reinforced nano silicon carbide composite ceramic material and preparation process thereof | 苏州奥耐特碳化硅陶瓷科技有限公司 | 2025-06-17 | — | — | CN | disclosed |
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7553831-B2 | Beta-secretase inhibitors; inhibiting cleavage of amyloid precursor protein (APP); hydroxy-functional disubstituted amines such as 6-(([[(2S,3S)-4-(3,5-difluorophenyl)-3-((3-[(dipropylamino)carbonyl]benzoyl)amino)-2-hydroxybutyl](ethyl)amino]carbonyl)amino)hexanoic acid | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7498436-B2 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY LLC (US) | 2009-03-03 | — | — | US | disclosed |
| WO-2008054454-A2 | NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF AS ANTIVIRAL AGENTS | TRANSTECH PHARMA, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008054454-A2 | NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF AS ANTIVIRAL AGENTS | TRANSTECH PHARMA, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| US-20080096942-A1 | Substituted Hydroxyethylamines | ELAN PHARMACEUTICALS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-7312360-B2 | Substituted hydroxyethylamines | ELAN PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070219239-A1 | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-09-20 | — | — | US | disclosed |
| US-20070219239-A1 | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-09-20 | — | — | US | disclosed |
| US-20070219239-A1 | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-09-20 | — | — | US | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC | 2007-09-13 | — | — | US | disclosed |
| US-7214715-B2 | Compounds to treat Alzheimer's disease | PHARMACIA & UPJOHN (US) | 2007-05-08 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-4036838-A | Process for the production of nitro derivatives of aromatic compounds | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096942-A1 | Substituted Hydroxyethylamines | BACE1, BACE2, MME | ALDH1A1 2044/4885MAPK1 3956/4885TP53 1060/4885 |
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, CHAT | ALDH1A1 524/4885MAPK1 3375/4885TP53 3792/4885 |
| US-20070219239-A1 | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | NUDT1, PNP, NME2 | ALDH1A1 2447/4885MAPK1 3463/4885TP53 1918/4885 |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | ALDH1A1 2133/4885MAPK1 3409/4885TP53 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.